Excision BioTherapeutics’ attempt to gene edit HIV disappoints. The company will now revamp vector: #ASGCT24
BALTIMORE — HIV patients who received a CRISPR-based gene editing treatment developed by Excision BioTherapeutics saw the virus rebound, and now the company is going back …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.